NEWSROOM

Biotechnology

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

Nov 6, 2024

Conference Call and Webcast on Tuesday, November 12, 2024, at 2:00 p.m. PT / 5:00 p.m. ET IRVINE, Calif., Nov. 6, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results on Tuesday, November 12, 2024, after U.S. market closes. The company will also host a conference call and webcast on Tuesday, November 12, 2024, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss...

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Lipella Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Nov 1, 2024

PITTSBURGH, PA, November 1, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (the “Company,” “our” or “us”), a clinical-stage biotechnology company focused on developing innovative therapies for serious diseases with unmet medical needs, today announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. Eastern Time on November 7, 2024 upon the filing of a certificate of amendment to the Company’s certificate of...

Digital Utilities Ventures Expands Dealer Network and Reports Strong Q1 Results, Setting the Stage for Continued Growth

Digital Utilities Ventures Expands Dealer Network and Reports Strong Q1 Results, Setting the Stage for Continued Growth

Oct 30, 2024

Mankato, MN, October 30, 2024 - PRISM MediaWire - Digital Utilities Ventures (OTC: DUTV) is pleased to announce the significant expansion of its sales force for its innovative modular Easy Nano Void Water Clean Up and Easy FEN Liquid Microbial Growth Systems. The Easy Nano Void Product Line now includes the “Shore Shed Model 30” that individual Lake Shore Owners can place next to shorelines. The technology utilizes no harmful chemicals and only trillions of tiny oxygen bubbles to quickly clean...

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

Oct 29, 2024

PITTSBURGH, Pa., Oct. 29, 2024 – PRISM MediaWire - Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Spartan Capital Investor Conference that is being held on November 4, 2024, at the Pierre Hotel in New York. Event: Lipella Presentation - 2024 Spartan Capital Investor Conference Date:...

Immunophotonics to Present at the 2024 ThinkEquity Conference

Immunophotonics to Present at the 2024 ThinkEquity Conference

Oct 28, 2024

St. Louis, Missouri, October 28, 2024 - PRISM MediaWire - Immunophotonics, Inc. a clinical-stage biotech company focused on the discovery and development of novel immune-activating drugs, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial...

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

Oct 24, 2024

Princeton, NJ, October 24, 2024 - PRISM MediaWire - Soligenix, Inc. (Nasdaq: SNGX) (“Soligenix” or the “Company”) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other...

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Oct 23, 2024

Glen Allen, VA, October 23, 2024 - PRISM MediaWire - Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other...

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

Oct 23, 2024

MIAMI, FL., October 23, 2024 – PRISM MediaWire - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate...

Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

Oct 23, 2024

Discoverer of Klotho gene further strengths KLTO Scientific Advisory Board New York, NY, October 23, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related diseases, is proud to announce the appointment of Dr. Makoto Kuro-o to its Scientific Advisory Board. Dr. Kuro-o, a distinguished Japanese physician-scientist, is widely recognized as the pioneer behind the discovery of the...

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

Oct 17, 2024

Retrospective Study demonstrates clinical efficacy and statistical support for tissue processed via BioREtain to care for treatment-resistant chronic wounds Study published in the peer-reviewed journal, ‘International Wound Journal’ POMPANO BEACH, Fla., Oct. 17, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived biologics for advanced wound care, announces breakthrough...

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

Oct 16, 2024

IRVINE, Calif., Oct. 16, 2024 - PRISM MediaWire - Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Event, hosted by LD Micro, on Tuesday, October 29th in Los Angeles. Oncocyte management will also be available for one-on-one meetings with investors. To schedule a one-on-one meeting, please contact Julie Silber at PCG Advisory (jsilber@pcgadvisory.com) or request a meeting via the LD Micro...

Join the Biofuels Brazil Forum 2024!

Join the Biofuels Brazil Forum 2024!

Oct 16, 2024

Biofuels Brazil Forum 2024 Join the Biofuels Brazil Forum 2024! New York, October 15, 2024 - We are pleased to announce that PRISM Mediawire will be one of the official Media partners for the upcoming International Investment Forum Biofuels Brazil 2024, which will take place from November 27 to 28, 2024, in São Paulo, Brazil. This forum is the premier platform for biofuel producers, regulatory bodies, government officials, technology pioneers, equipment suppliers, engineering companies, and...

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies Establishes National Pricing for Vendaje AC® from the Center for Medicare Services and Provides Reimbursement in All MAC Regions

Oct 15, 2024

Vendaje AC to launch across MAC regions nationwide through Venture Medical, the Company’s exclusive sales and marketing partner for AmnioWrap2® POMPANO BEACH, Fla., Oct. 15, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound care, today announced that the Center for Medicare Services (CMS) has established national pricing for its allograft...

Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

Co-Founder of Shire Pharmaceuticals Appointed as Chief Operating Officer of Klotho Neurosciences

Oct 15, 2024

KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidates New York, NY, October 15, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). “We are thrilled to have Peter join Klotho...

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform

Oct 15, 2024

Patent application covers key technology innovations for delivering therapeutic agents Proprietary technology enables precise delivery to improve safety and efficacy in oncology, cancer survivorship and immunotherapy Allowance provides broad IP protection for drug-delivery platform and extends market exclusivity for two lead clinical assets currently in Phase 2 trials PITTSBURGH, PA, October 15, 2024 - PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical-stage...

Lipella Pharmaceuticals to Present at 2024 Spartan Capital Investor Conference

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

Oct 9, 2024

PITTSBURGH, Oct. 09, 2024 - PRISM MediaWire - Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024. Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit Date: Thursday, October 17th, 2024...

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Oct 8, 2024

Results published in peer-reviewed journal, Clinical Cancer Research Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab DetermaIO targets a multi-billion-dollar addressable market in oncology diagnostics IRVINE, Calif., October 8, 2024 - PRISM MediaWire - Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced the peer-reviewed publication of positive data related to its proprietary gene expression test,...

Entrevista exclusiva com Newton Santana, Presidente e Diretor da BEVAP Bioenergia, em antecipação ao Biocombustíveis Brasil 2024

Oct 5, 2024

London, October 5, 2024 - PRISM MediaWire - Temos o prazer de compartilhar uma entrevista exclusiva com Newton Santana, Presidente e Diretor da BEVAP Bioenergia, em antecipação ao Biocombustíveis Brasil 2024 que acontecerá nos dias 27 e 28 de novembro em São Paulo. Newton Santana, Presidente e Diretor da BEVAP Bioenergia Nesta conversa perspicaz, Newton revela as estratégias de ponta da BEVAP para manter a liderança em inovação e sustentabilidade, ao mesmo tempo que oferece uma perspectiva...

Exclusive interview with Newton Santana, President and Director of BEVAP Bioenergy, ahead of Biofuels Brazil 2024

Oct 5, 2024

London, October 5, 2024 - PRISM MediaWire - We are pleased to share an exclusive interview with Newton Santana, President and Director of BEVAP Bioenergy, ahead of Biofuels Brazil 2024, which will take place on November 27-28 in São Paulo. Newton Santana, President and Director of BEVAP Bioenergy In this insightful conversation, Newton reveals BEVAP's cutting-edge strategies to maintain leadership in innovation and sustainability while offering a glimpse into the future of the biofuels...

Entrevista exclusiva con Newton Santana, Presidente y Director de BEVAP Bioenergía, en anticipación a Biocombustibles Brasil 2024

Oct 5, 2024

Londres, October 5, 2024 - PRISM MediaWire - Nos complace compartir una entrevista exclusiva con Newton Santana, Presidente y Director de BEVAP Bioenergía, en anticipación a Biocombustibles Brasil 2024, que se llevará a cabo los días 27 y 28 de noviembre en São Paulo. Newton Santana, Presidente y Director de BEVAP Bioenergía En esta conversación perspicaz, Newton revela las estrategias de vanguardia de BEVAP para mantener el liderazgo en innovación y sostenibilidad, al mismo tiempo que ofrece...

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

Oct 2, 2024

Company Obtains Participation from New and Existing Investors, Including Strategic Partner Bio-Rad Laboratories IRVINE, Calif., Oct. 02, 2024 - Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with new and existing investors, including Bio-Rad Laboratories, Inc., one of the Company’s strategic partners. The gross proceeds to the Company from the...

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies Initiates BR-AC-DFU-101 Clinical Trial to Study BioREtain® in Diabetic Foot Ulcers

Oct 2, 2024

Strategic head-to-head study of BR-AC vs. standard of care aims to demonstrate healing superiority potential to support increased payor coverage and market growth The study will be conducted in 60 patients at 10 sites across the U.S. and the first patients have begun treatment POMPANO BEACH, Florida, October 2, 2024 - BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for advanced wound...

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

Oct 1, 2024

Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System Jackson Center, PA, October 1, 2024 – PRISM MediaWire - Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veterans participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 access to mental health therapies provided by Yogani/Exalted Warrior Foundation....

BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment

BioStem Technologies, Inc. Files Form 10 with the Securities and Exchange Commission and Submits Nasdaq Application for Uplisting

Sep 30, 2024

Nasdaq listing aims to increase market visibility and global liquidity opportunities as BioStem advances its commercial and clinical initiatives amid record revenue growth Pompano Beach, FL, September 30, 2024 - PRISM MediaWire - BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a leading MedTech company focused on the development, manufacture and commercialization of placental-derived biologics, announces the filing of a Form 10 registration statement (the “Registration...

Dr. Makoto Kuro-o, Pioneer of the Klotho Anti-Aging Gene, Joins Klotho Neurosciences, Inc. as Scientific Advisor

Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)

Sep 30, 2024

Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics Development New York, NY, September 30, 2024 - PRISM MediaWire - Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific...

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month

Sep 25, 2024

NEW YORK, September 25, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Dr. Michael Chancellor, Co-founder and Chief Medical Officer of Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO). In this interview, Dr. Chancellor provides insights into the company's latest advancements in urological treatments, particularly in recognition of Urology Awareness Month, and discusses the significant progress made in the development of therapies for hemorrhagic cystitis (HC)....

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus

Sep 24, 2024

PITTSBURGH, Sept. 24, 2024 – PRISM MediaWire - Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced an update on its ongoing multi-center Phase 2a clinical trial evaluating LP-310 for the treatment of Oral Lichen Planus (OLP). The Company reported that three participants have completed the four-week treatment with LP-310, an oral rinse, with...

Digital Utilities Ventures Reports Strong Fiscal Year 2024 – Advancing Leadership in Green Technologies

Digital Utilities Ventures Reports Strong Fiscal Year 2024 – Advancing Leadership in Green Technologies

Sep 23, 2024

MANKATO, MN, September 23, 2024 - PRISM MediaWire - Digital Utilities Ventures, Inc. (OTC: DUTV), a leader in sustainable energy and environmental technologies, recently announced its financial results and corporate progress for the fiscal year ended May 31, 2024. The company demonstrated significant growth and strategic advancements, emphasizing its commitment to innovation and sustainable environment protecting technologies. Financial Highlights: Revenue Growth: The company reported net...

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology

Sep 13, 2024

NEW YORK, September 13, 2024 - PRISM MediaWire - PRISM MarketView presents an exclusive Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare technology company focused on chronic low back pain, Aclarion is at the forefront of developing noninvasive tools to help physicians identify the source of pain in spinal discs, potentially revolutionizing the standard of care for this widespread and debilitating condition. Aclarion's Nociscan platform,...

Projetos de destaque da indústria de biocombustíveis no Brasil em 2024

Sep 12, 2024

Projetos de destaque da indústria de biocombustíveis no Brasil em 2024 Solicite a lista completa New York, September 2024 - PRISM MediaWire -Em preparação para o Fórum Internacional de Investimentos em Biocombustíveis Brasil 2024, a Vostock Capital preparou um relatório que inclui a lista completa dos projetos de destaque da indústria de biocombustíveis no Brasil, que serão abordados em detalhe durante o evento. Entre os projetos: EXPANSÃO DA PRODUÇÃO DE ETANOL Empresa: Atvos, Investimento:...